Altimmune, Inc.'s Pemvidutide shows promise in MASH treatment with liver improvements and safety, despite market overreaction. Click for my ALT stock update.

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis ...

Michter’s 2025 Legacy Series features two limited releases: Bomberger’s Declaration Kentucky Straight Bourbon (54% ABV) and ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Madrigal Pharmaceuticals (NASDAQ:MDGL) and Viking Therapeutics (NASDAQ:VKTX) were among notable gainers on Thursday as ...

First product candidate to demonstrate significant MASH effects and weight loss at 24 weeks Trial met its primary endpoint with statistically significant MASH resolution without worsening of fibrosis ...

Drying out and heating up into the weekend ...

Shares of Altimmune tumbled after the company failed to achieve statistical significance on one of the dual primary endpoints in a recent trial evaluating its drug, pemvidutide, for metabolic ...

The clinical-stage biopharmaceutical company reported that the trial met its primary endpoint, with up to 59.1% of participants achieving MASH resolution without worsening of fibrosis in an ...

At the heart of Monsters Are Coming is the city. This bastion of civilisation is under siege by swarms of inky black spider-like monsters, but it’s not going to take this assault lying down. No, the ...

FOX21 Storm Team Meteorologist Robert Hahn took the Storm Squatch on the road to Downtown Colorado Springs to visit with folks at Mash Mechanix Brewing Co. on Thursday, June ...

ST. LOUIS — It wouldn’t be a Thursday morning on Show Me St. Louis without Dusty from 93.7 the Bull!